We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

This study has been terminated.
(Accrual was insufficient to meet study endpoints)
ClinicalTrials.gov Identifier:
First Posted: January 18, 2006
Last Update Posted: August 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of California, San Francisco

RATIONALE: Chemoprevention is the use of certain drugs to keep tumors from forming, growing, or coming back. Zoledronate may prevent the growth of cervical cancer by blocking blood flow to cervical intraepithelial neoplasia cells. The use of zoledronate may keep cancer from forming.

PURPOSE: This randomized is studying how well zoledronate works in treating patients with cervical intraepithelial neoplasia 2/3 or 3.

Condition Intervention Phase
Cervical Cancer Precancerous Condition Drug: zoledronic acid Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Enrollment: 12
Study Start Date: April 2005
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: zoledronate IV Drug: zoledronic acid
Placebo Comparator: placebo

Detailed Description:


  • Assess clinical response, in terms of lesion size and histological grade, of zoledronate in patients with cervical intraepithelial neoplasia 2/3 or 3.

OUTLINE: This is a randomized, placebo-controlled, double-blind, pilot study. Patients are stratified according to degree of cervical intraepithelial neoplasia (CIN) (CIN2/3 vs CIN3). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive zoledronate IV over 20 minutes on day 1.
  • Arm II: Patients receive placebo IV over 20 minutes on day 1. In both arms, treatment repeats every 21 days for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.

After completion of study treatment, patients are followed at week 10 by telephone.

PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Biopsy confirmed cervical intraepithelial neoplasia (CIN) 2/3 or 3

    • Planning loop excision or cone biopsy
    • Diagnosis within 2 months prior to study entry
    • Standard histological grading according to Richart
  • Visible lesion by colposcopy

    • No unsatisfactory colposcopy or lesions extending into the endocervical canal that cannot be visualized entirely by colposcopy
  • No suspicion of invasive cervical cancer by cytology, histology or colposcopy
  • No cytologic evidence of glandular atypia or dysplasia


  • Creatinine normal
  • Screening laboratory values within normal range (e.g., complete blood count, liver function tests, renal panel, and electrolytes)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to read and speak English or Spanish
  • No known hypersensitivity to bisphosphonates
  • Not immunocompromised
  • No known HIV positivity
  • No aspirin-sensitive asthma due to association of bisphosphonates with bronchoconstriction
  • No unexplained abnormal vaginal bleeding


  • No concurrent loop diuretics, aminoglycosides, other nephrotoxic drugs, immunosuppressive drugs, or other investigational agents
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00278434

United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
Sponsors and Collaborators
University of California, San Francisco
National Cancer Institute (NCI)
Study Chair: Karen Smith-McCune, MD, PhD University of California, San Francisco
  More Information

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00278434     History of Changes
Other Study ID Numbers: CDR0000460044
First Submitted: January 16, 2006
First Posted: January 18, 2006
Last Update Posted: August 5, 2013
Last Verified: August 2013

Keywords provided by University of California, San Francisco:
cervical cancer
cervical intraepithelial neoplasia grade 2
cervical intraepithelial neoplasia grade 3

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Cervical Intraepithelial Neoplasia
Precancerous Conditions
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Carcinoma in Situ
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Zoledronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs